Protein Sciences has published a manuscript in a peer-reviewed journal following extensive testing of the parent cells from which Protein Sciences’ proprietary expresSF+® (SF+) cell line is derived.

The study confirms that a contaminating rhabdovirus previously reported in a related cell line is not present in SF+ cells.

“The quality of our cells is of the utmost importance as they are the vehicle with which we make all of our vaccines,” said Dr. Manon Cox, President and CEO of Protein Sciences and senior author on the paper.

“The data in this paper further substantiate that SF+ cells are ideal for manufacturing – they can not only be scaled to very large volumes, allowing for the production of millions of doses of vaccine, but are also free of elements that have been reported for other Sf cell lines, such as rhabdovirus,” Dr. Cox said.